Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,233 | 170 | 95.0% |
| Education | $239.27 | 6 | 4.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $38.33 | 3 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $1,020 | 24 | $0 (2024) |
| GENZYME CORPORATION | $579.63 | 14 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $312.42 | 10 | $0 (2019) |
| Genentech USA, Inc. | $289.88 | 14 | $0 (2019) |
| Biogen, Inc. | $277.73 | 10 | $0 (2019) |
| Avanir Pharmaceuticals, Inc. | $247.15 | 9 | $0 (2019) |
| ACADIA Pharmaceuticals Inc | $243.64 | 10 | $0 (2019) |
| Eisai Inc. | $236.98 | 5 | $0 (2024) |
| UCB, Inc. | $235.23 | 9 | $0 (2019) |
| Novo Nordisk Inc | $228.51 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $458.29 | 5 | EMD Serono, Inc. ($133.69) |
| 2023 | $224.77 | 4 | Novo Nordisk Inc ($128.77) |
| 2022 | $351.32 | 7 | EMD Serono, Inc. ($261.58) |
| 2021 | $354.73 | 5 | EMD Serono, Inc. ($246.71) |
| 2020 | $141.91 | 5 | EMD Serono, Inc. ($141.91) |
| 2019 | $950.72 | 39 | GENZYME CORPORATION ($184.24) |
| 2018 | $1,260 | 51 | GENZYME CORPORATION ($234.65) |
| 2017 | $1,769 | 63 | Teva Pharmaceuticals USA, Inc. ($267.85) |
All Payment Transactions
179 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $99.74 | General |
| 08/15/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | Cash or cash equivalent | $133.69 | General |
| Category: Neurology | ||||||
| 05/16/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $67.86 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 03/23/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $33.29 | General |
| Category: Rare Disease | ||||||
| 03/06/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $123.71 | General |
| Category: Neurology | ||||||
| 12/01/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Rare Disease | ||||||
| 05/04/2023 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $76.88 | General |
| 03/10/2023 | EMD Serono, Inc. | MAVENCLAD (Drug) | Food and Beverage | Cash or cash equivalent | $73.76 | General |
| Category: Neurology | ||||||
| 02/16/2023 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $51.89 | General |
| 08/19/2022 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $72.13 | General |
| 08/10/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: NEUROSCIENCE | ||||||
| 05/25/2022 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | Cash or cash equivalent | $119.73 | General |
| Category: Neurology | ||||||
| 05/18/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: NEUROSCIENCE | ||||||
| 05/09/2022 | CATALYST PHARMACEUTICALS, INC. | FIRDAPSE (Drug) | Food and Beverage | Cash or cash equivalent | $26.43 | General |
| Category: NEUROLOGY | ||||||
| 02/08/2022 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $69.72 | General |
| 01/27/2022 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: NEUROSCIENCE | ||||||
| 09/10/2021 | EMD Serono, Inc. | — | Food and Beverage | In-kind items and services | $91.12 | General |
| 09/10/2021 | EMD Serono, Inc. | — | Food and Beverage | In-kind items and services | $65.73 | General |
| 05/28/2021 | EMD Serono, Inc. | — | Food and Beverage | In-kind items and services | $58.06 | General |
| 05/26/2021 | Biohaven Pharmaceuticals, Inc. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $108.02 | General |
| Category: PRIMARY CARE | ||||||
| 03/05/2021 | EMD Serono, Inc. | — | Food and Beverage | In-kind items and services | $31.80 | General |
| 11/06/2020 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | In-kind items and services | $27.75 | General |
| Category: Neurology | ||||||
| 10/02/2020 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: Neurology | ||||||
| 07/24/2020 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | In-kind items and services | $34.31 | General |
| Category: Neurology | ||||||
| 06/05/2020 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | In-kind items and services | $29.03 | General |
| Category: Neurology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 643 | 837 | $100,820 | $69,701 |
| 2022 | 10 | 679 | 889 | $115,899 | $79,850 |
| 2021 | 8 | 583 | 787 | $94,622 | $67,957 |
| 2020 | 11 | 605 | 761 | $86,013 | $54,094 |
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 241 | 406 | $39,024 | $25,487 | 65.3% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 35 | 35 | $17,336 | $12,644 | 72.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 82 | 82 | $14,650 | $10,370 | 70.8% |
| 95812 | Measurement of brain wave activity (eeg), 41-60 minutes | Facility | 2023 | 133 | 148 | $8,985 | $6,675 | 74.3% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 35 | 35 | $8,528 | $6,065 | 71.1% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 43 | 57 | $6,270 | $4,410 | 70.3% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 16 | 16 | $3,280 | $2,230 | 68.0% |
| 96136 | Administration of psychological or neuropsychological test, first 30 minutes | Office | 2023 | 29 | 29 | $1,460 | $945.27 | 64.7% |
| 96137 | Administration of psychological or neuropsychological test, each additional 30 minutes | Office | 2023 | 29 | 29 | $1,287 | $875.07 | 68.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 253 | 444 | $42,712 | $27,878 | 65.3% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2022 | 43 | 43 | $21,288 | $15,731 | 73.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 87 | 87 | $15,375 | $10,836 | 70.5% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2022 | 59 | 59 | $14,394 | $10,416 | 72.4% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 63 | 76 | $8,400 | $5,667 | 67.5% |
| 95812 | Measurement of brain wave activity (eeg), 41-60 minutes | Facility | 2022 | 93 | 99 | $6,608 | $4,559 | 69.0% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2022 | 11 | 11 | $2,222 | $1,667 | 75.0% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2022 | 14 | 14 | $2,268 | $1,509 | 66.5% |
| 96136 | Administration of psychological or neuropsychological test, first 30 minutes | Office | 2022 | 28 | 28 | $1,400 | $807.96 | 57.7% |
| 96137 | Administration of psychological or neuropsychological test, each additional 30 minutes | Office | 2022 | 28 | 28 | $1,232 | $778.74 | 63.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 214 | 397 | $38,000 | $25,882 | 68.1% |
| 95819 | Measurement and recording of brain wave (eeg) activity, awake and asleep | Office | 2021 | 36 | 36 | $17,358 | $13,781 | 79.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 104 | 104 | $18,607 | $13,193 | 70.9% |
| 95812 | Measurement of brain wave (eeg) activity, 41-60 minutes | Facility | 2021 | 103 | 114 | $7,708 | $5,421 | 70.3% |
| 95911 | Nerve transmission studies, 9-10 studies | Office | 2021 | 22 | 22 | $5,412 | $4,138 | 76.5% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 24 | 32 | $3,689 | $2,631 | 71.3% |
About Dr. Dean Karnaze, MD
Dr. Dean Karnaze, MD is a Specialist healthcare provider based in Stockton, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346276359.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dean Karnaze, MD has received a total of $5,510 in payments from pharmaceutical and medical device companies, with $458.29 received in 2024. These payments were reported across 179 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($5,233).
As a Medicare-enrolled provider, Karnaze has provided services to 2,510 Medicare beneficiaries, totaling 3,274 services with total Medicare billing of $271,602. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Practice Information
- Specialty Specialist
- Location Stockton, CA
- Active Since 06/23/2006
- Last Updated 10/21/2019
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1346276359
Products in Payments
- LEMTRADA (Drug) $419.23
- Mavenclad (Drug) $395.33
- NUPLAZID (Drug) $243.64
- NUEDEXTA (Drug) $242.84
- OCREVUS (Biological) $198.89
- RYTARY (Drug) $177.65
- TYSABRI (Biological) $169.09
- AUBAGIO (Drug) $160.40
- NAMZARIC (Drug) $136.19
- Briviact (Drug) $135.96
- APOKYN (Drug) $132.70
- ELIQUIS (Drug) $124.47
- Leqembi (Drug) $123.71
- Mavenclad (Biological) $120.84
- Fycompa (Drug) $113.27
- TECFIDERA (Drug) $108.64
- NURTEC ODT (Drug) $108.02
- EMGALITY (Drug) $105.18
- Vimpat (Drug) $99.27
- iFuse Implant (Device) $93.38
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Stockton
Gregory Bensch, M.d, M.D
Specialist — Payments: $1.8M
George Bensch, M.d, M.D
Specialist — Payments: $144,679
Dr. Ajithkumar Puthillath, Md, MD
Specialist — Payments: $33,046
Prasad Dighe, Md, MD
Specialist — Payments: $13,978
Aminder Mehdi, Md, MD
Specialist — Payments: $10,156
Josebelo Chong, Md, MD
Specialist — Payments: $7,732